Our Pricing

The Science Behind Do I Have To Increase My Mounjaro Dose

Many UK patients ask do I have to increase my Mounjaro dose UK after starting treatment, and the answer depends on your individual response and clinical goals. At Cured Pharmacy, our UK prescribers guide you through evidence-based titration schedules designed to maximise efficacy whilst minimising side effects. Understanding the science behind dose escalation helps you make informed decisions about your weight loss journey.

Understanding Mounjaro Dose Escalation: The Clinical Evidence

Mounjaro (tirzepatide) follows a structured dose escalation protocol established through the SURPASS clinical trial programme [1]. The medication is licensed in the UK with a starting dose of 2.5mg once weekly, designed primarily as a tolerability dose rather than a therapeutic endpoint. This initial four-week period allows your body to adapt to the dual GIP/GLP-1 receptor agonist mechanism whilst minimising gastrointestinal side effects.

Clinical trials demonstrated that higher maintenance doses correlate with greater weight reduction outcomes [1]. In the SURMOUNT-1 trial, participants receiving 15mg tirzepatide achieved an average 22.5% body weight reduction over 72 weeks, compared to 15% at the 10mg dose and 19.5% at the 5mg dose [2]. However, dose escalation must always be individualised based on tolerability, response, and clinical assessment by your UK prescriber.

The standard titration schedule increases the dose by 2.5mg increments every four weeks, progressing from 2.5mg to 5mg, then 7.5mg, 10mg, 12.5mg, and finally 15mg if clinically appropriate. Your prescriber may adjust this timeline if you experience persistent side effects or achieve your weight loss goals at a lower maintenance dose.

Do I Have To Increase My Mounjaro Dose? When Staying Lower Makes Sense

Dose escalation is not mandatory for every patient. Some individuals achieve significant weight loss and metabolic improvements at lower maintenance doses such as 5mg or 7.5mg weekly [3]. Your UK prescriber will assess multiple factors including your rate of weight loss, tolerability profile, baseline BMI, and presence of weight-related comorbidities when determining whether to continue escalation.

Clinical practice recognises that optimal dosing varies considerably between patients. If you're experiencing satisfactory weight loss (typically 1-2kg per week initially, then 0.5-1kg weekly during maintenance), have manageable side effects, and are progressing toward your clinical goals, your prescriber may recommend maintaining your current dose rather than escalating further. This personalised approach balances efficacy with quality of life.

Conversely, if weight loss plateaus before reaching your target, or if you're tolerating the medication well without significant side effects, dose escalation may enhance outcomes. The MHRA-approved prescribing information supports flexible dosing strategies based on individual patient response, and your Cured Pharmacy prescriber will review your progress regularly to optimise your treatment plan.

Side Effects and Dose Tolerance

Gastrointestinal side effects including nausea, vomiting, diarrhoea, and constipation are most common during dose escalation phases [1]. These effects typically diminish within days to weeks as your body adapts. If side effects are severe or persistent, your prescriber may extend the time between dose increases or maintain you at a lower dose indefinitely. There is no clinical requirement to reach the maximum 15mg dose if a lower dose meets your therapeutic objectives whilst maintaining better tolerability.

The Mounjaro Titration Schedule: What UK Prescribers Recommend

The MHRA-licensed titration protocol for Mounjaro in the UK follows a structured four-week escalation pattern. Week 1-4 begins at 2.5mg once weekly, followed by an increase to 5mg for weeks 5-8, then 7.5mg for weeks 9-12, 10mg for weeks 13-16, 12.5mg for weeks 17-20, and finally 15mg from week 21 onwards if clinically indicated [4].

This gradual escalation minimises the risk of gastrointestinal adverse events whilst allowing your body to adapt to increasing GLP-1 and GIP receptor stimulation. Each dose increment triggers enhanced satiety signalling, delayed gastric emptying, and improved insulin sensitivity, with cumulative effects building over time. Your UK prescriber will monitor your response at each stage through regular clinical reviews.

At Cured Pharmacy, our clinical team assesses your progress every four to eight weeks during the escalation phase. This includes reviewing weight loss trajectory, side effect profile, adherence, and any changes to your medical history. Based on this comprehensive evaluation, your prescriber will determine whether to proceed with escalation, maintain your current dose, or adjust the treatment plan to optimise outcomes whilst prioritising your wellbeing.

Maintenance Dosing Strategies

Once you reach a maintenance dose that delivers effective weight loss with acceptable tolerability, you typically continue at that level long-term. Clinical trials used maintenance doses ranging from 5mg to 15mg weekly, with most participants remaining on their assigned dose throughout the study period [1][2]. Your maintenance dose becomes your therapeutic dose, and further escalation is only considered if weight loss plateaus or clinical circumstances change.

Mounjaro vs Wegovy: Comparing Dose Escalation Protocols

Understanding how Mounjaro's titration differs from other GLP-1 treatments helps contextualise dose escalation requirements. Wegovy (semaglutide) follows a similar gradual escalation pattern, starting at 0.25mg weekly and increasing monthly to a target maintenance dose of 2.4mg [5]. However, Mounjaro's dual GIP/GLP-1 mechanism produces greater average weight loss at equivalent escalation timeframes.

The key difference lies in the therapeutic range and receptor targets. Whilst Wegovy has a single maintenance dose (2.4mg), Mounjaro offers multiple maintenance options from 5mg to 15mg, allowing more personalised dosing based on individual response. Clinical head-to-head data suggests tirzepatide produces 5-7% greater body weight reduction compared to semaglutide at the highest licensed doses [2][5].

Both medications require prescription and clinical oversight in the UK. At Cured Pharmacy, Mounjaro is available from £135.00 and Wegovy from £135.00 with final pricing determined by your prescribed dose and treatment duration. Your UK prescriber will discuss which medication and dose escalation protocol best suits your clinical profile, weight loss goals, and tolerance for potential side effects.

When to Pause or Reduce Your Mounjaro Dose

Certain clinical situations warrant pausing dose escalation or temporarily reducing your Mounjaro dose. Persistent gastrointestinal symptoms lasting beyond two weeks at a new dose, significant dehydration, inability to maintain adequate nutrition, or development of acute pancreatitis symptoms all require immediate prescriber review and potential dose adjustment [4].

If you experience a period of illness, particularly conditions causing vomiting or diarrhoea, your prescriber may recommend temporarily holding your Mounjaro injection or reverting to a lower dose until you recover. Similarly, if you're scheduled for surgery requiring general anaesthesia, your surgical team may advise temporarily discontinuing Mounjaro due to its gastric emptying effects.

Pregnancy is an absolute contraindication for Mounjaro use, and the medication should be discontinued at least two months before planned conception [4]. If you become pregnant whilst taking Mounjaro, stop the medication immediately and contact your prescriber. Your Cured Pharmacy clinical team provides ongoing support for dose adjustments and can modify your treatment plan promptly when circumstances change.

Restarting After a Treatment Break

If you've been off Mounjaro for more than four weeks, your prescriber will typically restart you at a lower dose than where you left off, often returning to the 2.5mg starting dose. This approach minimises side effects when reintroducing the medication and allows re-titration at an appropriate pace. Your previous tolerance doesn't guarantee the same tolerance upon restarting, particularly after extended breaks.

Optimising Your Mounjaro Treatment at Cured Pharmacy

Successful Mounjaro treatment extends beyond dose escalation to encompass lifestyle modifications, dietary adjustments, and regular clinical monitoring. At Cured Pharmacy, our UK prescribers provide comprehensive treatment plans that integrate medication with behavioural strategies proven to enhance weight loss outcomes in clinical trials [1][2].

Your treatment journey begins with a thorough online clinical assessment taking under three minutes, reviewed by our UK-registered prescribers. We provide transparent upfront pricing with Mounjaro available from £135.00 and all consultations are provided free of charge. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees clinical governance, ensuring every prescription meets MHRA and NICE guidelines for safe, effective weight management.

We offer discreet packaging and convenient delivery across the UK, with ongoing prescriber access for dose adjustments, side effect management, and clinical reviews. Whether you're just starting your Mounjaro journey or considering dose escalation, our clinical team provides evidence-based guidance tailored to your individual circumstances. All prescription medications require clinical assessment by a UK prescriber, and treatment is subject to prescriber approval based on your medical history and suitability.

Additional Weight Loss Options

If Mounjaro isn't suitable or you're exploring alternatives, Cured Pharmacy offers a comprehensive range of UK-licensed weight loss treatments. Options include Wegovy (semaglutide) injections, Saxenda (liraglutide) daily injections, and oral medications such as Orlistat and Xenical. Your prescriber will discuss the most appropriate option based on your clinical profile, preferences, and weight loss goals during your consultation.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
3. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
4. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/14395/smpc
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and treatment is subject to prescriber approval based on individual suitability.